相关实验视频

Updated: Jun 29, 2025

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles

Published on: November 1, 2017

基于pyridoxine的多克索鲁比辛衍生物的抗癌潜力:一个体外研究

Rawdah Karwt¹, Oksana V Bondar¹, Mikhail V Pugachev¹

¹Scientific and Educational Center of Pharmaceutics, Kazan (Volga Region) Federal University, Kazan 420008, Russia.

Life (Basel, Switzerland)

|March 28, 2024

概括

为了减少副作用,合成了两种新的氧化衍生物多克索鲁比衍生物. DOX-2通过向细胞循环和细胞亡而不是DNA,显示出选择性的抗癌活性和更好的安全性概况.

科学领域:

药用化学医学化学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

多克索鲁比 (DOX) 是一种广泛使用的化疗药物.
DOX表现出显著的心脏毒性和骨髓抑制,限制了其临床应用.
开发更安全,更有效的抗癌药物至关重要.

研究的目的:

合成新型的皮里多克素衍生的多克索鲁比衍生物 (DOX-1和DOX-2).
研究DOX-1和DOX-2的抗瘤活性和作用机制.
与DOX相比,评估这些衍生品的安全性.

主要方法:

化学合成DOX-1和DOX-2具有不同的链接长度.
在实验室中对各种癌细胞系和正常细胞的细胞毒性进行评估.
细胞周期分析,细胞亡测定 (线粒体通路) 和抗氧化活性评估.
对DNA相互作用的研究以阐明机制.

主要成果:

具有C3链接器的DOX-2对癌细胞具有增强的选择性,对正常细胞具有有利的安全性.
具有C1链接器的DOX-1缺乏选择性的抗瘤作用.
通过线粒体通路,DOX-2诱导细胞循环停止和细胞亡,表现出抗氧化特性.
与DOX不同,DOX-2与核DNA没有相互作用.

结论:

DOX-2是一种有前途的新型抗癌治疗剂,具有提高的选择性和安全性.
DOX-2的作用机制涉及细胞周期调节和亡诱导,与DOX的DNA向方法不同.
需要进一步的体内研究来探索DOX-2的治疗潜力.

关键词:

它们是DNA插曲.抗癌剂是一种抗癌剂.抗氧化剂抗氧化剂是一种抗氧化剂.诱导性亡诱导性亡细胞循环逮捕细胞循环逮捕德克索鲁比辛 (doxorubicin) 是一种药物.德克索鲁比的衍生物多克索鲁比的衍生物皮里多克辛 (pyridoxine) 是一种素.维生素B6 维生素B6 是一种维生素.

更多相关视频

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...